Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 5 years of Non-Current Deffered Revenue readings, the most recent being $31.8 million for Q1 2026.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $31.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $31.8 million, a 0.0% change, with the full-year FY2025 number at $31.8 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue hit $31.8 million in Q1 2026 for Kiniksa Pharmaceuticals International, roughly flat from $31.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $31.8 million in Q4 2024 to a low of $261000.0 in Q4 2023.
  • Median Non-Current Deffered Revenue over the past 5 years was $12.0 million (2023), compared with a mean of $18.4 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 97.82% in 2023 and later surged 12088.12% in 2024.
  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $12.0 million in 2022, then crashed by 97.82% to $261000.0 in 2023, then surged by 12088.12% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025, then changed by 0.0% to $31.8 million in 2026.
  • The last three reported values for Non-Current Deffered Revenue were $31.8 million (Q1 2026), $31.8 million (Q4 2025), and $31.8 million (Q3 2025) per Business Quant data.